Phospho-ERK1/2 (Thr202/Tyr204) Recombinant monoclonal antibody Proteintech 80031-1-RR
$299.00
In stock
SKU
80031-1-RR
ERK (Thr202/Tyr204), ERK1/2 (Thr202/Tyr204), ERK2 (Thr185/Tyr187), p ERK, p ERK (Thr202/Tyr204)
| Formulation:：PBS, Azide, Glycerol | Formulation:：PBS, Azide, Glycerol1 |
| Applications：Western Blot (WB) | Formulation:：PBS, Azide, Glycerol2 |
| Reactivity：Human, Mouse, Rat | Formulation:：PBS, Azide, Glycerol3 |
| Type：Antibody | Formulation:：PBS, Azide, Glycerol4 |
| RRID：NM_002746 | Formulation:：PBS, Azide, Glycerol5 |
| Storage Buffer：Unconjugated | Formulation:：PBS, Azide, Glycerol6 |
| Background Information：Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. This antibody simultaneously recognizes the phosphorylation of ERK1 at Thr202 and Tyr204, as well as the phosphorylation of ERK2 at Thr185 and Tyr187. | Formulation:：PBS, Azide, Glycerol7 |
| biogegep8 | Formulation:：PBS, Azide, Glycerol8 |
| biogegep9 | Formulation:：PBS, Azide, Glycerol9 |
| Formulation:：PBS, Azide, Glycerol0 | Applications：Western Blot (WB)0 |
Reviews
Write Your Own Review
Related Products
Check items to add to the cart or
